Cystic fibrosis

Area of Science:

• Genetics
• Molecular Biology
• Pulmonology

Background:

• Cystic fibrosis (CF) is a rare genetic disease stemming from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• CFTR protein dysfunction disrupts ion and fluid transport, leading to multi-organ disease, primarily muco-obstructive lung disease.
• Historically, CF care focused on symptom management, including nutritional support, airway clearance, and antibiotics.

Purpose of the Study:

• To review the discovery of CFTR and the evolution of CFTR-directed therapeutics.
• To highlight the impact of recent CFTR modulator therapies on the CF treatment landscape.
• To identify the unmet medical needs in the CF population.

Main Methods:

• Literature review of CFTR discovery and therapeutic development.
• Analysis of the clinical benefits and limitations of current CFTR modulator therapies.
• Examination of the current unmet medical needs in CF patient populations.

Main Results:

• The discovery of CFTR enabled understanding of disease mechanisms and development of targeted therapies.
• Highly effective triple combination CFTR modulator therapy has transformed prognosis for up to 90% of eligible patients.
• A significant unmet medical need persists for CF patients ineligible for or lacking access to current modulator therapies.

Conclusions:

• CFTR modulator therapies represent a breakthrough, fundamentally altering CF care.
• Despite advances, a substantial portion of the CF population still requires novel therapeutic strategies.
• Further research and equitable access are crucial to address the remaining challenges in cystic fibrosis treatment.